Dr. Padte joined RenBio at pre-incorporation, led the company’s formation and early-stage growth, and currently oversees all scientific-, operations- and business-related activities for the company. He has over 10 years of experience managing scientific, legal, financial and regulatory activities related to the discovery and development of novel antibody and vaccine clinical candidates. This includes the management of strategic alliances with industry, government and academic partners that contributed to the acquisition of >$40M in private and government funding awards.
Dr. Padte also has technical expertise managing discovery through IND/Phase 1 development activities. As Director of Product Development at the Aaron Diamond AIDS Research Center and in close partnership with David D. Ho, MD and Yaoxing Huang, PhD, Dr. Padte advanced the novel bispecific antibody, 10E8.4/iMab, from discovery to first-in-human clinical testing. 10E8.4/iMab is the first bispecific antibody against an infectious disease to be tested in humans and received Fast Track designation by the U.S. FDA. Earlier in his career, Dr. Padte worked at Praulex, Inc., a start-up biotechnology company in the Princeton, NJ area acquired by Amersham Pharmacia Biotech (currently GE Healthcare Life Sciences). Dr. Padte received his PhD in Cellular, Molecular and Biophysical Studies from Columbia University and his Bachelor of Arts in Biochemistry and Molecular Biology from Boston University.